# Table 4 Comparison of associations of composite endpoints with MDA response across time points and studies

Tofacitinib 5 mg BID
N = 68
Tofacitinib 10 mg BID
N = 62
N = 66
Tofacitinib 5 mg BID
N = 64
Tofacitinib 10 mg BID
N = 62
STB R STB R STB R STB R STB R
Month 3
PASDAS −0.73* −0.19 −0.71 −0.13 −0.70* −0.20 −1.23** −0.26 −0.53 0.00
DAPSA 0.64 0.10 0.09 0.00 0.35 0.00 0.38 0.00 0.87* 0.23
CPDAI −0.07 0.00 0.15 0.00 −0.33 −0.02 0.17 0.00 −0.71 −0.16
DAS28–3(CRP) −0.58 −0.06 −0.34 0.00 −0.11 0.00 −0.08 0.00 −0.75* −0.22
Month 6
PASDAS −0.91* −0.20 −0.83* −0.17 −0.61 −0.12 −1.27* −0.21 −0.77* −0.16
DAPSA 0.78 0.15 0.83 0.15 0.47 0.04 0.82* 0.21 1.00** 0.26
CPDAI 0.08 0.00 −0.00 0.00 −0.17 0.00 −0.48 0.00 0.04 0.00
DAS28–3(CRP) −0.53 −0.08 −1.23** −0.26 −0.42 −0.11 −0.44 0.00 −0.69* −0.20
Month 12
PASDAS −1.02** −0.29 −0.87* −0.18 −1.88*** −0.35
DAPSA 0.79** 0.24 0.51 0.04 0.86 0.11
CPDAI 0.08 0.00 −0.09 0.00 −0.00 0.00
DAS28–3(CRP) −0.68* −0.20 −0.75* −0.19 −0.18 0.00
1. *P≤0.05, **P<0.01, ***P<0.001 testing the null hypothesis that the slope coefficient is equal to 0, based on the Wald statistic from the multiple logistic regression model
2. N = number of patients included in the multiple logistic regression model
3. For a given time point and treatment group, a multiple logistic regression was performed on MDA evaluated at this time point as a dependent variable and the changes from baseline in the composite endpoints measured at the same time point as predictors. The slope coefficient for a composite endpoint from this regression model is standardized (STB) to permit comparison of the associations of these composite endpoints with the MDA response. An additional statistic, logistic pseudo partial correlation (R, range − 1 to 1), was also computed as a measure of correlation between the composite endpoints and MDA response 
4. Abbreviations: BID twice daily, CPDAI Composite Psoriatic Disease Activity Index, DAPSA Disease Activity Index for Psoriatic Arthritis, DAS28–3(CRP) 3-component Disease Activity Score using 28 joints with C-reactive protein, MDA minimal disease activity, OPAL Oral Psoriatic Arthritis triaL, PASDAS Psoriatic Arthritis Disease Activity Score, Q2W once every 2 weeks, SC subcutaneous